Monitoring drug levels to improve outcomes in metastatic kidney cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness and side effects of treatment drugs in patients with metastatic renal cell carcinoma (mRCC) by monitoring plasma drug concentrations. It also investigates the role of anti-drug antibodies and genetic variations in CTLA-4 and PD-1 receptors that may contribute to treatment failure. Additionally, the study will explore correlations between UGT1A1 gene polymorphisms and pazopanib dosing. The goal is to optimize treatment regimens and identify patients who may not benefit from certain therapies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients in Denmark with medically treated metastatic renal cell carcinoma.

Exclusion Criteria:

* No written informed consent.

Where it's running

• Department of Oncology, Aarhus University Hospital
  Aarhus, Danmark, Denmark Recruiting

Study contacts

• Principal investigator: Niels Fristrup, MD, PhD — University of Aarhus
• Study coordinator: Niels Fristrup, MD, PhD
• Email: niels.fristrup@rm.dk
• Phone: +4520914161

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Deferred surgery for kidney cancer with metastases

  This study is testing whether waiting to do kidney surgery after starting treatment for kidney cancer with metastases can help patients live longer compared to having surgery right away.

  Recruiting at 11 sites University of Aarhus · Aarhus, Central Region of Denmark and 10 other locations · NCT03977571

• Your Kidney Cancer Immunotherapy: How You Get It and If Labs Can Be At Home

  This study tests whether people with kidney cancer prefer intravenous or subcutaneous immunotherapy and whether at‑home lab draws plus telehealth visits before treatment are practical.

  Recruiting at 7 sites Phase 4 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07872553

• Perioperative UDCA to Protect Kidney Function in Partial Nephrectomy

  This study tests whether giving ursodeoxycholic acid around surgery can help protect kidney function in adults having partial nephrectomy for kidney tumors.

  Recruiting Phase 2 Jinling Hospital, China · Nanjing, Jiangsu · NCT07672860

• Side Effects and Resource Navigation Program for Cancer Patients

  This program tests whether a navigation service helps adults with kidney, bladder, breast, or lung cancer manage immunotherapy better than usual care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 7 other locations · NCT07646847

• EBNK-001 allogeneic NK cell therapy with low-dose IL-15, with or without pembrolizumab, for advanced solid tumors

  This treatment tests an off-the-shelf NK cell product (EBNK-001) given with low-dose IL-15, either alone or with pembrolizumab, in adults with advanced or metastatic solid tumors who have exhausted standard options.

  Recruiting Phase 1/2 Essen Biotech · Beijing, Beijing Municipality · NCT07410676

• HC-7366 plus nivolumab with or without ipilimumab for advanced clear-cell kidney cancer (SHARK)

  This trial tests whether adding HC-7366 to nivolumab, with or without ipilimumab, can help control advanced clear-cell kidney cancer.

  Recruiting at 2 sites Phase 1 M.D. Anderson Cancer Center · Dallas, Texas and 1 other locations · NCT07401875

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.